Terumo Introduces New Proprietary Oxygenator to Market.
Offered at an NHI reimbursement price of 208,000 yen ($1,890), the new oxygenerator is suitable for use for a wide range of patients from infants to adults.
Japan has about 40,000 cardiac surgeries a year. Terumo is aiming for sales of 400 million yen ($3.6 mil) in fiscal 2005. The company also plans to market the CAPIOX RX15 overseas, first in Asia and then in Europe and the US.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Sep 13, 2005|
|Previous Article:||Takeda Pharmaceutical's ACTOS Oral Antidiabetic Agent Proves in the PROactive Study to Reduce Risk of Heart Attack and Stroke in Type 2 Diabetics.|
|Next Article:||CTC to Market Symyx Technologies' e-Lab Notebook Solution for Chemists.|